Roche's Genentech division has reported disappointing top-line results from its highly-anticipated phase 3 trial of gantenerumab in early Alzheimer's disease, in yet another setback for an
The FDA is planning to take an additional three months to review Biogen's experimental therapy for amyotrophic lateral sclerosis (ALS), setting back its decision date from January to April.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
